Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsors and Collaborators: |
Mylan Bertek Pharmaceuticals None |
---|---|
Information provided by: | Mylan Bertek Pharmaceuticals |
ClinicalTrials.gov Identifier: | NCT00200421 |
The purpose of this study is to determine the effects on exercise capacity of nebivolol compared to atenolol in hypertensive patients.
Condition | Intervention | Phase |
---|---|---|
Hypertension |
Drug: Nebivolol and Atenolol |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Active Control, Parallel Assignment, Safety Study |
Official Title: | A Double-Blind, Randomized, Multi-Center, Active Comparator, Five Treatment Study of the Effects of Nebivolol Compared to Atenolol on Cardiovascular Hemodynamics and Exercise Capacity in Patients With Mild to Moderate Hypertension |
Estimated Enrollment: | 110 |
Study Start Date: | May 2002 |
Estimated Study Completion Date: | August 2003 |
This was a pilot, phase II, double-blind, randomized, muticenter, active-comparator, five treatment parallel group dosing and mechanistic study. The study consisted of two phases: 1) screen/washout/single-blind placebo run-in and 2) randomization/treatment. There was a minimum of five scheduled study visits.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, West Virginia | |
Mylan Pharmaceuticals Inc. | |
Morgantown, West Virginia, United States, 26505 |
Study Director: | Betty S. Riggs, MD, MBA | Mylan Pharmaceuticals |
Study ID Numbers: | NEB203 |
Study First Received: | September 12, 2005 |
Last Updated: | December 15, 2005 |
ClinicalTrials.gov Identifier: | NCT00200421 History of Changes |
Health Authority: | United States: Food and Drug Administration |
Nebivolol Atenolol Exercise Hypertension |
Neurotransmitter Agents Vasodilator Agents Adrenergic Agents Vascular Diseases Nebivolol Cardiovascular Agents Antihypertensive Agents |
Adrenergic beta-Antagonists Adrenergic Antagonists Peripheral Nervous System Agents Anti-Arrhythmia Agents Atenolol Hypertension |
Vasodilator Agents Neurotransmitter Agents Sympatholytics Molecular Mechanisms of Pharmacological Action Adrenergic Agents Physiological Effects of Drugs Vascular Diseases Nebivolol Cardiovascular Agents Antihypertensive Agents |
Pharmacologic Actions Autonomic Agents Therapeutic Uses Adrenergic beta-Antagonists Adrenergic Antagonists Cardiovascular Diseases Anti-Arrhythmia Agents Peripheral Nervous System Agents Atenolol Hypertension |